May 2017

The latest from Cogstate, leaders in optimizing the measurement of cognition

Cogstate Selected as Preferred Provider to Lilly’s Alzheimer’s Disease Platform

May 17, 2017

Company to Deliver Novel Solutions to Ensure High-quality Neuropsychological Measures in Clinical Trials New Haven, CT – May 17, 2017: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced it has been chosen as the preferred provider to the global healthcare leader, Eli Lilly and Company, to support their Alzheimer’s disease platform with solutions to ensure […]

Cogstate Brief Battery Effective For Detecting Cognitive Impairment in Pediatric MS Patients

May 12, 2017

While multiple sclerosis (MS) is most often diagnosed in adults, symptoms can begin much earlier in life. Pediatric onset MS (POMS) affects 8,000-10,000 children under the age of 18 in the U.S., while an additional estimated 10,000 have at least one symptom. Diagnosis can be difficult as physicians often default to more common childhood disorders […]

Cogstate Brief Battery Shows Correlation With Traditional Tests of Cognition In Breast Cancer Population

May 1, 2017

As the complexity and geographic distribution of clinical trials increase, there is a growing need for more efficient cognitive testing of participants. Traditional “pencil and paper” neuropsychological tests have been the gold standard but require expert administration and manual data collection. To scale to hundreds of patients located around the world, computerized cognitive testing offers […]